LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
To evaluate the efficacy and safety of LM108 plus toripalimab plusnab-paclitaxel or eribulin as first-line or post-line treatment in patients with metastatic triple-negative breast cancer.
TNBC - Triple-Negative Breast Cancer
DRUG: LM-108|DRUG: Toripalimab|DRUG: Eribulin|DRUG: Nab paclitaxel
ORR, Objective Response Rate, 6 weeks
DoR, Duration of overall response, 6 weeks|DCR, Disease control rate, 6 weeks|PFS, Progression-free survival, 6 weeks|OS, Overall survival, 6 weeks|Adverse events, Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, 6 weeks
To evaluate the efficacy and safety of LM108 plus toripalimab plusnab-paclitaxel or eribulin as first-line or post-line treatment in patients with metastatic triple-negative breast cancer.